Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April July May June August September October November December
Previous Archive
07 July 2023 | Story André Damons | Photo Supplied
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), with his certificate after winning the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

A research paper by a Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS) has won the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa.

The abstract, by Dr Osayande Evbuomwan, was about evaluating the efficacy of a new nuclear medicine radiopharmaceutical in the identification of active disease in patients with rheumatoid arthritis. It was selected for this award by a special committee at the recently concluded SNMMI 2023 Annual Meeting, which took place between 24 and 27 June in Chicago, USA.

Dr Evbuomwan received the award at the Annual Meeting on 26 June.

“It is a good feeling, and I am proud of the UFS Department of Nuclear Medicine for pulling this off. It is another example that hard work pays,” he says.

Comparing this radiopharmaceutical to ultrasound

Dr Evbuomwan says the research that generated the award-winning abstract was aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. The study concluded that this particular radiopharmaceutical (Tc – 99m glucosamine) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints), and is capable of offering prognostic information in patients with rheumatoid arthritis.

This is the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says. He is currently working on comparisons of this radiopharmaceutical to ultrasound and clinical evaluation in the identification of active disease in patients with rheumatoid arthritis. He says there is also ongoing collaboration with the Rheumatology Division of the Internal Medicine Department, which has played a huge role in making this project fruitful.

“This award is an opportunity to put the department and university on the map, with world stage recognition. We believe that as the Nuclear Medicine Department continues to grow in human resources and equipment, the research output will also increase.”

Dr Gerrit Engelbrecht, Clinical Head of the Department of Nuclear Medicine at the UFS, says the whole department is very proud of Dr Evbuomwan’s accomplishments. “What makes his award even more remarkable is that he outperformed candidates from much larger, highly funded institutions,” he says.

This department announced last year the successful treatment outcome of a patient with metastatic castrate-resistant prostate cancer (MCRPC) – an advanced stage of prostate cancer – by using Lutetium 177 PSMA (Lu-177 PSMA) therapy. This was initially a case of advanced stage prostate cancer, which had failed first-line chemotherapy, leaving little or no other treatment options.

News Archive

UFS waives application fees for studies in 2016
2015-10-22

The University of the Free State (UFS) has waived application fees for all prospective undergraduate and postgraduate students - nationally and internationally - who want to study at the institution in 2016.

"Universities charge application fees that vary in amount. With 25 universities in South Africa, this fee becomes a burden for students who want to apply to more than one university. The university leadership has also realised that tens of thousands of students who qualify for university entrance stumble at the first hurdle: finding the money to apply,” says Prof Jonathan Jansen, Vice-Chancellor and Rector.

According to Prof Jansen, the UFS would like to set an example and a challenge to all public universities to scrap the application fee, so that many more young people from poor communities can realise their dream of accessing higher education. At the same time, the universities will benefit from more top talent coming into higher learning. "The more students that enrol and graduate, the stronger the financial position of universities will be; it is a win-win policy, and the university leadership has done the maths on this," he says.
 
The application fees for 2016 were R235 for South African students and R500 for international students. Prospective students, who have already applied for admission in 2016, will not be refunded. However, students who have already registered successfully for 2016 may apply to have the application fee credited to their tuition fee account after they have registered next year.
 
To support this initiative, UFS Marketing will be conducting an on-site application campaign by visiting East London, Port Elizabeth, Kimberley, Qwaqwa, Kathu, Pretoria, Johannesburg, Newcastle, Durban, Pietermaritzburg, and Ladysmith from 28 August 2015. Further details of the venues in each town will be available on the Kovsie2b Facebook page.

All prospective students currently doing their final-year undergraduate studies at either the UFS or any other university will also pay no registration fee if they want to continue with an Honours degree in 2016. The registration fee for 2016 was R950.
 
The closing date for applications for admission is 31 December 2015.

Apply for undergraduate or postgraduate studies at the UFS for 2016.

For enquiries, please call +27(0)51 401 9111.

 

 

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept